Gilead Q4 Sales and Profit Slightly Top Estimates as 2026 Guidance Lands at Low End of Street Expectations
Gilead Sciences reported fourth-quarter adjusted earnings per share of $1.86 on revenue of $7.9 billion, modestly above analyst estimates. Sales of the twice-yearly HIV prevention injection Yeztugo and the HIV treatment Biktarvy both beat Wall Street forecasts for the quarter. For 2026, management set guidance that sits at the lower bound of analys…